Stifel Nicolaus Initiates Biotie Therapies At Buy

Monica Gerson , Benzinga Staff Writer

July 06, 2015 9:34am Comments

Analysts at Stifel Nicolaus initiated coverage on Biotie Therapies Oyj (ADR) (NASDAQ: BITI) with a Buy rating.

The target price for Biotie Therapies is set to $30.

Biotie Therapies' shares rose 4.02 percent to $19.13 in pre-market trading.

Date	Firm	Action	From	To
Apr 2016	Roth Capital	Terminates	Neutral
Mar 2016	RBC Capital	Downgrades	Outperform	Sector Perform
Jul 2015	Roth Capital	Initiates Coverage on		Buy

Posted-In: Stifel Nicolaus Initiation Analyst Ratings

Need analyst data?
Click here to see licensing options.

Stock	Firm	Action	PT
IBIO	Cantor Fitzgerald	Initiates Coverage On	3.0
WNS	Needham	Maintains	85.0
THC	UBS	Maintains	60.0
UPLD	Canaccord Genuity	Maintains	57.0
E	Jefferies	Initiates Coverage On

1	DJIA, SPY: How Trump's Stock Market Return Compares To Obama, Bush And Other...
2	TSLA: If You Bought Tesla Stock Instead Of A Model S At Launch, Here'...
3	AVGR, LAC: 40 Stocks Moving in Wednesday's Pre-Market Session
4	ADXN, NDRA: 42 Stocks Moving in Thursday's Pre-Market S...
5	BABA: Why Jack Ma's Reappearance Isn't E...
6	FCEL: FuelCell Energy's Earnings Outlook
7	MA, ETHE: Why This Analyst Can See Ethereu...

1	GBTC: Janet Yellen Changes Stance On Cryptocurrencies After Causing Bitcoin Plunge
2	AAPL, FB: Apple VR Headset To Arrive In 2022 And At A Steep Price: Report
3	BABA: Alibaba-Backed Ant Group's Valuation Estimated To Drop To $108B
4	GBTC: 'Double Spending' Chaos Leads To Bitcoin Plunging...
5	SPOT, AAPL: Spotify Brings On Board Filmmaker Ava DuVernay Wit...
6	GILD, PFE: Pfizer, GSK-Backed ViiV First To Get FDA...
7	ACBI: Atlantic Capital: Q4 Earnings Insights

Market Overview